| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,400 |
4,400 |
4,400 |
4,400 |
| Total Buy Value |
$49,771 |
$49,771 |
$49,771 |
$49,771 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
70,000 |
86,548 |
100,059 |
106,283 |
| Total Sell Value |
$933,231 |
$1,178,206 |
$1,271,354 |
$1,340,256 |
| Total People Sold |
1 |
4 |
4 |
4 |
| Total Sell Transactions |
2 |
7 |
12 |
16 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-04-16 |
4 |
AS |
$14.20 |
$710,195 |
D/D |
(50,000) |
604,205 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-04-16 |
4 |
OE |
$0.99 |
$25,588 |
D/D |
25,846 |
654,205 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-04-04 |
4 |
AS |
$11.15 |
$223,036 |
D/D |
(20,000) |
628,359 |
|
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-14 |
4 |
B |
$11.31 |
$49,771 |
D/D |
4,400 |
171,620 |
0.01 |
- |
|
| Garcia Peter S |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
110,348 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
93,591 |
|
- |
|
| Randolph Sophia |
CHIEF MEDICAL OFFICER |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
342,349 |
|
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
167,220 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
648,359 |
|
- |
|
| Pinto Shelly |
SVP, Finance and CAO |
• – – |
2024-01-04 |
4 |
S |
$13.60 |
$36,957 |
D/D |
(2,717) |
78,591 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2023-12-29 |
4 |
S |
$15.04 |
$47,045 |
D/D |
(3,128) |
312,349 |
|
- |
|
| Pinto Shelly |
SVP, Finance and CAO |
• – – |
2023-12-29 |
4 |
S |
$15.04 |
$24,530 |
D/D |
(1,631) |
81,308 |
|
- |
|
| Pons Jaume |
President & CSO |
• • – |
2023-12-29 |
4 |
S |
$15.04 |
$107,972 |
D/D |
(7,179) |
618,359 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
S |
$15.04 |
$28,471 |
D/D |
(1,893) |
85,348 |
|
- |
|
| Pinto Shelly |
SVP, Finance and CAO |
• – – |
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
81,713 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
89,000 |
625,538 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
315,477 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
86,738 |
|
- |
|
| Pinto Shelly |
VP, Finance and CAO |
• – – |
2023-07-06 |
4 |
S |
$6.52 |
$47,889 |
D/D |
(7,345) |
55,713 |
|
- |
|
| Pinto Shelly |
VP, Finance and CAO |
• – – |
2023-06-30 |
4 |
S |
$7.34 |
$3,420 |
D/D |
(466) |
63,058 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2023-06-30 |
4 |
S |
$7.34 |
$23,547 |
D/D |
(3,208) |
536,538 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2023-06-30 |
4 |
S |
$7.34 |
$11,781 |
D/D |
(1,605) |
281,477 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
S |
$7.34 |
$6,511 |
D/D |
(887) |
54,738 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2023-06-09 |
4 |
OE |
$1.91 |
$48,171 |
D/D |
12,829 |
283,082 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2022-12-29 |
4 |
S |
$11.07 |
$35,779 |
D/D |
(3,232) |
539,746 |
|
- |
|
101 Records found
|
|
Page 1 of 5 |
|
|
